Meet Mantis’ team: co-founder, Denis Hellebuyck
Hey there! Ever wondered about the awesome people who make things happen behind the scenes? We are starting our journey to meet the team now! Can you talk a bit about your background, expertise and role at Mantis Photonics? I have a bachelor degree in...
Choroidal Naevi Breakthrough: Navigating Success with Hyperspectral Imaging Studies
Choroidal Naevi are pigmented lesions observed beneath the retina, in the choroid region of the eye, similar to the pigment spots you can see on your skin. While less common than their cutaneous counterparts, skin naevi or moles, they are observed in about 10% of the...
Eyes on the future: Early detection of AMD through Hyperspectral Imaging
Age-related macular degeneration is a progressive disease and a leading cause of irreversible blindness in individuals above 50 years of age. It affects over 200 million people worldwide with around 2 million suffering complete vision loss and 6 million having severe...
Breaking news: CLINICAL TRIAL VALIDATES CUTTING-EDGE ANALYSIS FOR AMD!
Age-related Macular degeneration (AMD) is the leading cause of blindness in the western world with 200 million people affected and causing 4 million cases of Blindness. Treatments exist but are very expensive and painful as they require injections in the eye. In an...
What is the potential of hyperspectral retinal imaging?
In 2016, Google has published a deep learning algorithm to detect diabetic retinopathy (DR) called Automated Retinal Disease Assessment (ARDA)¹. The model trained on more than 100,000 retinal images was able to "identify key markers of diabetic retinopathy, such as...
Webinar’s Q&A
Mantis Photonics conducted a webinar on January 11th 2024, aiming to introduce the company to potential investors. Following the meeting, a question and answer (Q&A) session occurred, you can find the transcription directly below. For additional information, view...
Mantis Photonics’ crowdfunding campaign gaining momentum
Mantis Photonics, a Swedish medical technology company developing non-invasive and portable hyperspectral imaging solutions for early disease detection, has surpassed the 50% funding milestone in its ongoing crowdfunding campaign on Capital Cell. This significant...
JOIN OUR NEWSLETTER
Don’t miss out on our latest news and content!